Biocon Fund Raise of ₹200 Cr

Biocon Board Meeting Date

Biocon schedules a November 4, 2026 board meeting for Q2 FY27 unaudited results, plus an earnings call. Trading window stays closed until November 6, 2026.

Biocon Business Update

Biocon signed a licence agreement with Janssen to commercialise biosimilar Yesintek in nine more markets, including Australia, Brazil and China. No deal value is disclosed.

Biocon Other Announcement

Biocon Ltd has submitted its quarterly shareholding pattern for the period ended September 30, 2026. The filing details the distribution of equity shares among various stakeholder categories.

Biocon Partnership

Biocon entered a global patent settlement and license agreement with Genentech, securing early launch dates for its biosimilar Pebrilzo® (bPertuzumab) across key global markets.

From

Genentech

Biocon Legal & Regulatory

Biocon received a GST demand order for ₹3.21 Crore, including tax, interest, and penalty. The company intends to file a rectification application or appeal.

Value

₹3.21 Cr

Biocon Employee Stock Options

Biocon Limited announced the grant of 94,60,232 stock options to eligible employees under its Biocon Unity Long Term Incentive Plan 2026.

Rite Zone Chemcon India Fund Raise of ₹6.58 Cr

Rite Zone Chemcon India announced a preferential issue of 27,69,730 equity shares to 11 investors at Rs.24 each, raising about Rs.6.58 Crore. The approval awaits a shareholder vote on 23 November 2026.

Value

₹6.58 Cr

Sudarshan Pharma Industries Fund Raise of ₹72 Cr

Sudarshan Pharma's board approved up to Rs. 72 Crore of preferential convertible warrants for promoters Hemal and Sachin Mehta. Shareholder approval will be sought at an EGM.

Value

₹72.00 Cr

Flywings Simulator Training Centre Fund Raise of ₹68.2 Cr

Flywings Simulator's board approved Rs. 68.20 Crore fully convertible warrants on a preferential basis. Promoter Rupal Mandavia is allotted Rs. 25 Crore, subject to shareholder approval.

Value

₹68.20 Cr

Kanel Industries Fund Raise of ₹16.99 Cr

Kanel Industries' board approved a rights issue of 42.52 lakh equity shares at Rs.39.95 each. The issue aggregates about Rs.16.99 Crore, with record date 13 November 2026.

Value

₹16.99 Cr

Execution

Rights issue opens 23 November 2026 and closes 30 November 2026

Sudarshan Pharma Industries Fund Raise

Board approved issuing up to 72 Crore warrants to promoters on a preferential basis. Pricing per Reg 164 is pending, with no fixed rupee value stated.

GAIL (India) Fund Raise

GAIL Board approved in principle the IPO of subsidiary GAIL Gas Limited on Indian exchanges. GAIL will dilute its GGL equity up to 25%.